Analyst firms · Oppenheimer · TARS
Oppenheimer TARS price target and rating history
Tarsus Pharmaceuticals Inc. (TARS) · Health Care
Oppenheimer rates Tarsus Pharmaceuticals Inc. (TARS) Outperform with a $98 price target, as of its latest action on Apr 24, 2026. It has published 3 rating actions on TARS since November 2021, including 0 upgrades and 0 downgrades. Across 4 firms with a TARS price target in the last 12 months, the median target is $105. Oppenheimer's $98 is 7% below that.
- Current rating
- Outperform
- Price target
- $98
- Median target, all firms
- $105
- Actions on TARS
- 3
Oppenheimer price target on TARS
Every Oppenheimer rating on TARS
- Apr 24, 2026
- Jun 2, 2025
- Nov 23, 2021
How other firms rate TARS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Goldman Sachs | Buy | $116 | Sep 24, 2026 |
| Barclays | Overweight | $110 | Sep 16, 2026 |
| Oppenheimer | Outperform | $98 | Apr 24, 2026 |
| Mizuho | Outperform | $100 | Nov 20, 2025 |
Questions about Oppenheimer and TARS
- What is Oppenheimer's price target for TARS?
- Oppenheimer's latest stated price target for Tarsus Pharmaceuticals Inc. (TARS) is $98, from its action on Apr 24, 2026.
- What is Oppenheimer's rating on TARS?
- Oppenheimer rates TARS Outperform, a bullish rating, as of Apr 24, 2026.
- When did Oppenheimer last change its view on TARS?
- On Apr 24, 2026, Oppenheimer resumes coverage at Outperform, price target $105 to $98.
- How does Oppenheimer's TARS target compare with other analysts?
- Across 4 firms with a TARS price target in the last 12 months, the median target is $105. Oppenheimer's $98 is 7% below that.
More TARS rating histories
All Oppenheimer ratingsTARS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.